Androgen Deprivation Therapy News and Research

RSS

New treatment approach effectively treats the most aggressive forms of prostate cancer

Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

19 Sep 2023

Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

28 Aug 2023

Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s disease

The association between Androgen Deprivation Therapy (ADT) and the risk of dementia.

16 Aug 2023

Copy number profiling provides insight as to why prostate cancer may become lethal

Researchers performed genome-wide copy number profiling of the androgen receptor (AR) on metastases from deceased prostate cancer patients.

16 Aug 2023

Researchers validate first-ever AI biomarker for ADT benefit in prostate cancer

Data from a new study published in NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer.

30 Jun 2023

Study investigates whether metformin mitigates androgen deprivation therapy-related metabolic syndrome

A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, "Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer."

21 Jun 2023

Phase 3 studies for rectal, brain, and kidney cancers to be presented by Dana-Farber researchers at ASCO 2023

Several phase 3 studies conducted by researchers from Dana-Farber Cancer Institute show promising results for patients with rectal, brain, and kidney cancers. The results of these studies, along with dozens of others led by Dana-Farber researchers, will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

26 May 2023

Declining PSA levels predict improved survival rates in men with non-metastatic castration-resistant prostate cancer

Declines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology, an Official Journal of the American Urological Association.

10 Feb 2023

Rising Medicare costs linked to increased use of new prostate cancer therapies

Medicare costs for treatment of metastatic prostate cancer have risen sharply within the last 15 years – reflecting increased use of new medications under Medicare Part D, reports a study in Urology Practice, an Official Journal of the American Urological Association.

20 Dec 2022

Study shows benefits of metastasis-directed therapy without ADT for oligorecurrent prostate cancer

For patients with solitary metastases from prostate cancer, an approach called metastasis-directed therapy (MDT) – focused treatment using surgery or radiation therapy, without androgen deprivation therapy (ADT) – can slow the time to cancer progression, reports a study in The Journal of Urology, an Official Journal of the American Urological Association

10 Nov 2022

$38,398 for a single shot of a very old cancer drug

Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn't been going out long when she laid down the law: He had to get a physical.

26 Oct 2022

Clinical trial confirms the safety, efficacy of shortened radiation therapy for high-risk prostate cancer patients

A new randomized study confirms that men with high-risk prostate cancer can be treated with five versus eight weeks of radiation therapy.

24 Oct 2022

Is male hypogonadism a risk factor for hospitalization for COVID-19?

Researchers found an association between male hypogonadism and hospitalization risk for COVID-19.

7 Sep 2022

How does COVID-19 affect sexual and bladder functions in men?

Researchers discuss the impact of COVID-19 on the urogenital health of males.

1 Aug 2022

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy.

16 Jun 2022

Androgens contribute to sex bias in bladder cancer

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.

10 Jun 2022

New androgen biosynthesis inhibitor drug for prostate cancer shows mixed results

A new androgen biosynthesis inhibitor drug improved progression-free survival in prostate cancer but did not improve overall survival compared to current therapies, according to a study published in the Journal of Clinical Oncology.

31 May 2022

Combined treatment approach proves to be beneficial for prostate cancer patients

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy-;a commonly used hormone injection-;plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.

26 May 2022

The link between androgens and COVID-19

A new paper examines the association between androgens and COVID-19, as revealed by the research carried out on this topic throughout the pandemic.

20 May 2022

Understanding sex differences in the pathophysiology of SARS-CoV-2 infection

A recent study published in the journal Immunology analyzed whether sex mattered in the immune response to SARS-CoV-2.

29 Apr 2022